Pathological Microscopes Market By Key Vendors, Regions, Trends With Industry Study & Forecast To 2023

 Market Scenario

The growth of the healthcare sector in conjunction with the rising prevalence of diseases is expected to create demand for advanced equipment over the next couple of years. A study conducted by Market Research Future (MRFR) on the pathological microscopes market projects that a CAGR of 4.50% over the assessment period 2018 to 2023. The report further underlines that the market is expected to scale a valuation of USD 523.20 Mn towards the close of 2023.

The increasing burden of diseases such as cancer, diabetes, tuberculosis, etc. is anticipated to intensify the demand for pathological equipment that facilitates early detection and diagnosis. It is projected to pave the way for innovation and development of devices that offer accuracy. This, in turn, is anticipated to have a favorable impact on the growth pattern of the pathological microscopes market in the years to come.

The automation drive witnessed in the laboratories is also projected to accelerate revenue creation for market participants. Again, the increasing count of laboratories and pathology labs are expected to propel the expansion of the pathological microscopes market size over the next few years.

Competitive Analysis

Microscope manufacturers in the pathological microscopes market include Nikon Corporation (Japan), Leica Biosystems Nussloch GmbH (Germany), Olympus Corporation (Japan), ZEISS International (Germany), Labomed, Inc. (U.S.), Hitachi High-Technologies Corporation (Japan), Euromex Microscopen BV (The Netherlands), Bruker Corporation (U.S.), Sakura Finetek USA, Inc. (U.S.), and Celestron LLC (U.S.).

The players are focusing on integrating new technologies to expedite the diagnosis rate associated with microscopes and lower the mortality rate. Collaborations, new product launches, and partnerships are strategies being adopted to gain a larger market share.

Segmentation

The pathological microscopes market is segmented by type, application, and end-user.

By type, electron microscope held close to 41.4% share in 2017, followed by optical microscope (18.8%), compound microscope (13.5%), digital microscope (5.4%), fluorescence microscope (4.4%), and others (16.5%). Electron microscopes can generate nearly USD 217.81 million by 2023 owing to their application in life sciences. Prevalence of diseases such as anemia and leukemia which require the need of electron microscopes lend credence to the segment valuation. But digital microscopes can exhibit the highest CAGR of 5.01% during the forecast period to accumulate USD 28.90 million for the pathological microscopes market by 2023.

By end-user, pathology & diagnostic laboratories accounted for 45.2% market share in 2017, followed by hospitals & clinics (38.6%), forensic laboratories (11.5%), and others (4.7%). Hospitals & clinics will be the biggest end-user of the pathological microscopes market by 2023. It can generate USD 206.25 million by the end of the forecast period owing to the setup of various branches of hospital chains to handle high patient volume. On the other hand, pathology & diagnostic laboratories can generate USD 239.73 million by 2023 thanks to possessing various skilled personnel and use of hematology, clinical microbiology, and molecular pathology for rapid diagnosis of diseases.

By application, bodily fluids accounted for 79.4% share of the pathological microscopes market in 2017, followed by tissue scanning (12.7%), and others (7.9%). Bodily fluids can generate USD 418.84 million for the pathological microscopes market by 2023. This can be attributed to use of fluid samples to identify the presence of diseases such as tuberculosis in the human body. High prevalence of blood disorders is driving the segment growth. On the other hand, tissue scanning is touted to accumulate USD 67.94 million by 2023. High prevalence of cancer and use of digital microscopes to detect abnormal tissue growth can fuel the segment growth.

Regional Analysis

The global pathological microscopes market, by region, has been segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa (MEA). Americas is expected to gain control over the maximum market share during the review period. The regional market is projected to touch a valuation of USD 190.98 Mn by the end of 2023. The advancements of laboratories being observed in the region are expected to drive the growth of the pathological microscopes market in the nearby future.

Asia Pacific is projected to exhibit healthy growth owing to the rapid developments in the healthcare sector. The pathological microscopes market in the region is anticipated to attract massive investments over the next couple of years, thus, augmenting the market.

Industry News:

In March 2019, Nikon Instruments Inc., a leader in advanced optical instruments, has announced a partnership with OptraSCAN, On-Demand Digital Pathology Solution Provider, for the launch of OS-15-N, a digital slide scanning system that features Nikon optics.

In January 2019, Roche, a Swiss multinational healthcare company, has announced the introduction of its uPath enterprise software for digital pathology.

Access More Report Details @  https://www.marketresearchfuture.com/reports/pathological-microscopes-market-7319 

Global Microbiology Testing Market 2020 - Investment Strategy, Outlook And Key Development Till 2023

 Market Scenario

The Global Microbiology Testing Market Size is expected to register 10.4% CAGR and is anticipated to reach USD 5409.1 6 Million by 2023. Microbiology testing services help to lower the potential damage risk by microbes and to ensure that the microbiology quality of the products is maintained. The microbial testing technique includes chemical, biological, biochemical, or molecular methods to quantify and identify microbes.

Technological advancements, rising cases of infectious diseases, surveillance programs for disease control, increasing stringency of standards, weakness of traditional laboratory techniques are the major drivers propelling market growth. However, erroneous results and high cost of reagents and instruments may constrain the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/697

Key Players

The prominent players in the global microbiology testing market are, Beckman Coulter, Inc. (a subsidiary of Danaher Corp), BioMérieux SA, Thermo Fisher Scientific Inc., Cepheid (a subsidiary of Danaher), and F. Hoffmann-La Roche Ltd.

Some of the key strategies followed by the players operating in the global microbiology testing market were innovation, product development, acquisition, and expansion.

Market Dynamics

Technological advancements are expected to drive the growth of the market. For instance, according to the data published by the National Centre for Health Statistics in 2017, there were around 9,272 cases of tuberculosis infectious disease. Additionally, rising cases of infectious diseases, surveillance programs for disease control, increasing stringency of standards, weakness of traditional laboratory techniques are likely to support market growth. On the other hand, erroneous results and high cost of reagents and instruments are anticipated to hamper the market growth.

Segmentation

The global microbiology testing market has been segmented into product type, application, and end user. 

Based on type, the global market has been segmented into instruments, chemicals & reagents, consumables & accessories, and others. The instruments segment accounted for a market value of USD 954.9 million in 2016.

Based on application, the global market has been segmented into gastrointestinal infections, respiratory infections, urinary tract infections, sexually transmitted infections, and others.

Based on end user, the global market has been segmented into hospital associate laboratory, independent laboratory, and academic and research institutes.

Regional Analysis

The global microbiology testing market, based on region, is segmented into North Americas, Europe, Asia-Pacific, and the Middle East & Africa.

North America is estimated to dominate the global microbiology testing market during the forecast period. This can be attributed to the rapid adoption of advanced products and techniques. The European market for microbiology testing is expected to be the second-largest during the forecast period. Increasing innovation and changing laboratory practices is expected to boost the growth of the market in this region.

Asia-Pacific is estimated to be the fastest-growing market due to increasing funding for R&D, developing healthcare infrastructure, growing awareness about microbiology testing, government initiatives to improve public health, and growing investments by major players. Moreover, in the region, South Korea accounted for a market share of 9.2% in 2016.

The market in the Middle East & Africa is expected to witness steady growth due to limited access to healthcare facilities, lack of knowledge of new microbiology testing techniques, less funding R&D, and limited availability to equipment.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/microbiology-testing-market-697

Over-the-Wire Micro-Guide Catheter Market Overview With Detailed Analysis, Competitive Landscape, Forecast To 2023

 Over-the-wire Micro Guide Catheter (OTW Micro Guide Catheter) is a thin tubular Medical device inserted into the body for diagnosis or treatments of diseases like cardiovascular, neurovascular, and urology. Specially designed to ease complex procedures, OTW Micro Guide Catheter combining excellent cross-ability and optimal guide-wire support, can effectively treat challenging cases involving tortuous vessels, CTO (chronic total occlusions), bifurcations, and highly stenosed and calcified lesions, giving the high success rate.

OTW Catheters are widely used in cardiovascular applications such as peripheral and coronary interventions and neurovascular interventional applications. The high success rate associated with the use of these catheters further augments its uptake and demand, resultantly driving its market growth.

According to Market Research Future (MRFR)’s global Over-the-wire Micro Guide Catheters market Size Forecast, the industry is expected to grow at a CAGR of 9.37% during the forecast period (2018–2023).

According to reports published by the Centers for Disease Control and Prevention, the coronary heart disease is the most common type of heart diseases that accounted for the death of about 366,000 people in 2015.

Over-the-wire catheters comparatively make a better choice to treat a brain aneurysm than the rapid exchange catheters owing to their capabilities of extra pushing to enter stenose vessels, and additional support that they provide.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6078

The increasing occurrences of coronary heart diseases, neurovascular diseases, hypertension, and other metabolic disorders, raising awareness for health, advancement in technologies, good healthcare infrastructure, and favorable reimbursement policies are fueling the market growth. 

Regional Analysis

The global over-the-wire micro guide catheters market is segmented into four regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa. Americas is the global market leader for over-the-wire Micro-guide catheters. As per the study published in the Surgical Neurology International in 2017, it was found that more than 3% population of the United States equivalent to nearly 10 million individuals have a brain aneurysm. North America commands for the major share of the market whereas; South America show the fastest growth of the market due to the presence of boundless growth opportunities.

Europe OTW Micro Guide Catheter market holds the second position, globally. This is primarily attributable to the increasing prevalence of obesity as well as the increased incidence rate of hypertension and diabetes, which in turn is escalating cardiovascular traumas and cardiac arrest. Each year 15% of deaths in Europe occur due to cardiovascular diseases claims a study conducted by European Society of Cardiology.

The Asia Pacific region is the fastest growing market for the over-the-wire micro guide catheters. The region presents significant growth opportunities for market players as local policy makers continue to restructure the policy framework for the healthcare sector.

Global OTW Micro Guide Catheter Market: Segmentation

The global over-the-wire micro guide catheters market is segmented on the basis of applications and end-users. On the basis of applications, it is segmented into cardiovascular and neurovascular. By the cardiovascular, it is segmented into angiography, angioplasty, peripheral stenting, and others. On the basis of the neurovascular, it is segmented into intracranial aneurysms, percutaneous neurointerventional procedures, and others. Based on end-user the market is segmented into hospitals & clinics, ambulatory surgical centers, research & academic institutes, and others.  

Major Players in the Over-the-wire Micro Guide Catheters Market

Enki – Microtubes, Cardinal Health, DePuy Synthes, Koninklijke Philips N.V, Penumbra Inc., Terumo Europe N.V., Integer Holdings Corporation, Merit Medical Systems Inc., Teleflex Incorporated, Cook Medical, Boston Scientific Corporation, Asahi Intecc Company Limited, and Medtronic plc.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/over-the-wire-micro-guide-catheter-market-6078

Herbal Medicine Market Overview With Detailed Analysis, Competitive Landscape, Forecast To 2023

 The Global Herbal Medicine Market value is expected to register a CAGR of 5.88% to reach USD 1,29,689.3 million by 2023.

Herb is a plant or plant part used for its scent, flavor, or therapeutic properties. Herbal medicines are a type of dietary supplements. They are sold as tablets, capsules, powders, teas, extracts, and fresh or dried plants. People use herbal medicines to maintain and improve their health. Many conventional drugs originate from plant sources, and most of the few effective drugs are plant-based. Examples include aspirin (from willow bark), digoxin (from foxglove), quinine (from cinchona bark), and morphine (from the opium poppy). The development of drugs from plants continues, with drug companies engaged in the large-scale pharmacologic screening of herbs.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/3250

Key Players

The prominent players in the global herbal medicine market are Arkopharma, Bayer AG, BEOVITA, Hishimo Pharmaceuticals, Schaper & Brümmer, ZeinPharma Germany GmbH, Venus Pharma GmbH, Dasherb Corp, and Arizona Natural Products among other.

Some of the key strategies followed by the players operating in the global herbal medicine market were innovation, product development, acquisition, and expansion.

Market Dynamics

Herbal medicines are used since ancient times for numerous health conditions. It is the oldest and most extensively used system of medicine in the world today. There are various kinds of herbal medicines and supplements used across the world. According to the National Center for Biotechnology Information, 2015, the World Health Organization (WTO), reported that around 70% to 80% of people globally rely on herbal sources for their treatment. Also, according to the American Botanical Council, September 2017, it was reported that in 2016, the sale of herbal supplements increased by 7.7% in the US. It was also estimated that consumers spending on herbal supplements increased to USD 7.452 billion in 2016. Thus, the increase in the demand for herbal products for healthcare purposes is likely to enhance this market during the forecast period.

Segmentation

The global herbal medicine Market, by category, is segmented into herbal pharmaceuticals, herbal dietary supplements, herbal functional foods, and herbal beauty products. The herbal pharmaceutical segment led the herbal medicine market with USD 50,972.4 million in 2017. The herbal pharmaceutical segment is growing owing to the increasing research and development on various herbs to find their medicinal properties, growing demand for natural medicines having fewer side-effects, and rising prevalence of chronic diseases such as diabetes, arthritis, cancer, sleep disorders, and digestive problems.

Marrubium vulgare segment is the fastest-growing segment of the market at CAGR of 6.45% during the forecast period. Marrubium vulgare also known as white horehound is a largely cultivated plant, and its above-ground parts are used for medicinal use. The upper part of the plant is used in powder, liquid extract, or juice form for medicinal purposes. Marrubium vulgare is largely used for digestion problems which include indigestion, loss of appetite, gas, bloating, diarrhea, constipation, and gallbladder complaints. It is also used for the treatment of breathing problems

The global herbal medicine Market, by form, is segmented into extracts, powders, capsules and tablets, syrups, and others. The extracts segment accounted for the largest market share of 36.95% in 2017.

The global herbal medicine Market, by source, is segmented into leaves, fruit, roots, and barks whole plant, and others (combinations of various plant parts). On the basis of source, the leaves segment is expected to lead the global herbal medicine market. The leaves segment held a share of USD 51,495.2 million in 2017.

The global herbal medicine Market, by distribution channel, is segmented into hospital and retail pharmacies, e-commerce, and others. The hospital & retail pharmacies segment accounted for the largest market share of 55.82% in 2017. The growing prevalence of cancer and infectious diseases across the globe, improving healthcare infrastructure, and skilled professionals are driving the growth of hospital and retail pharmacies in the herbal medicine market.

Regional Analysis

Europe is expected to account for the largest market share owing to extensive R&D for herbal medicine, increasing funding for research on medicinal plants, and growing preference for herbal drugs globally. On a regional basis, Europe is segmented into Western Europe and Eastern Europe. Western Europe is estimated to lead market growth during the forecast period. The increasing prevalence of chronic diseases and rising government support facilitate market growth within the region.

Americas accounts for the second largest share in the global herbal medicine market. It accounted for a considerable market share of 16.2% as of 2017. The use of herbal medicines is also growing in the US after conducting the first national study of alternative and complementary medicines used by Eisenberg et al. According to the National Center for Biotechnology Information 2017, it was reported that herbal supplements were majorly used for conditions such as cancer (43.1%), stroke (48.7%), and arthritis (43%) in the US. Such a high demand and preference for herbal products is likely to boost the market growth during the forecast period.

Asia-Pacific is expected to register a CAGR of 5.99% during the forecast period owing to the adoption of traditional medicines by pharmaceutical companies, researchers, and policymakers. On the other hand, the Middle East and Africa are expected to observe a slow growth due to less awareness and in-depth knowledge about herbal drugs in this region.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/herbal-medicine-market-3250 

Vocal Cord Paralysis Market Global Analysis, Size, Share, Trends, And Forecast 2020 To 2023

 Market Dynamics

Vocal Cord Paralysis Market is driven by rising prevalence of causing factors of vocal cord paralysis and technological advancements. For instance, according to the American Cancer Society, the estimated number of new cancer cases involving larynx was 13,360 in the US for the year 2017. Moreover, increasing healthcare expenditure has fueled the growth of the market. On the other hand, the high cost of treatment is anticipated to hamper the market growth.

Market Scenario

The Global Vocal Cord Paralysis Market Growth is expected to register a CAGR of 3.8%and is anticipated to reach USD 2,920.2 Million by 2023. Vocal cord paralysis is caused by the disruption of nerve impulses to the muscles of the larynx or voice box. It may be caused by injury to the head, neck, or chest; lung or thyroid cancer; tumors of the neck or chest; or infection. The nerves controlling the vocal cords are long and can be vulnerable to injury in parts of the body, not usually associated with the vocal cords.

The increasing prevalence of causing factors of vocal cord paralysis, technological advancements, and growing healthcare expenditure are the major drivers propelling market growth. However, the high cost associated with the treatment is expected to constrain the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5079

Competitive Landscape

Key players in the vocal cord paralysis market include Cytophil, Inc. (U.S.), Teleflex Incorporated (U.S.), Medtronic Plc (U.S.), Olympus Corporation (Japan), Stryker Corporation (U.S.), FUJIFILM Holdings Corporation (Japan), LifeCell Corporation (U.S.), Therapy Solutions Inc. (U.S.), KARL STORZ GmbH & Co. KG (Germany), and Smiths Group Plc (U.K.).

The report offers a comprehensive analysis on the profiles on these market players and assesses their current standing in the market. Company history coupled with annual turnover, profit margins, segmental share, SWOT analysis, growth strategies, expansion techniques, and latest R&D initiatives are discussed in minute detail.

Segmentation

By type, the market is divided into unilateral and bilateral. Treatment options in the vocal cord paralysis market voice therapy and surgery. The surgery treatment segment is further divided into structural implants, tracheotomy, bulk injection (phonosurgery), and vocal cord repositioning. The segments covered in the vocal cord paralysis market report are analyzed with respect to four regions namely – Americas, Middle East & Africa (MEA), Asia Pacific (APAC), and Europe. The report discusses in detail the various players residing in these regions and their respective strategies to climb up the market standings.

Regional Analysis

By region, the global vocal cord paralysis market has been segmented into the Americas, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA).

The Americas accounted for the largest share of 35.4% share of the global market in 2017 and is due to reach USD 1,007.5 Mn in 2023 at a CAGR of 3.4% by the end of the forecast period. Robust healthcare sector, technological superiority, and rising expenditure ion healthcare sector drive the market in the Americas. In addition, the region is highly aware of the medical condition which is acts a plus for the growth of the market.

Europe is a prominent market for vocal cord paralysis and is likely to scale valuation of USD 958.1 Mn at a CAGR of 4% by the end of the forecast period. Similar factors spur the Europe market as the Americas. Also, favorable reimbursement policies and high government support create a conducive environment for the growth of the Europe vocal cord paralysis market.

APAC vocal cord paralysis market is likely to exhibit rapid growth over the forecast period and emerge as the fastest growing market over the forecast period. The increasing prevalence of laryngeal cancer, availability of affordable treatment options and high expenditure on healthcare drive the market in APAC. The APAC market is expected to capture a CAGR of 4.11% over the forecast period.

The MEA market for vocal cord is expected to hold the least share of the market and expand at a CAGR of 3.90% over the forecast period.

Browse Vocal Cord Paralysis Market Report Information by Type, Treatment and Region @ https://www.marketresearchfuture.com/reports/vocal-cord-paralysis-market-5079

Medical Drones Market 2020 Global Trend, Segmentation And Opportunities, Forecast 2025

 Market Forecast

Medical Drones’ Market size is expected to worth USD 398 Million by 2025 and is anticipated to register a CAGR of 24.4% during the forecast period (2019 to2025).

Market Synopsis

Medical drones help in the transport of medical supplies such as vaccines, medications, and medical aids. These drones are deployed in remote or inaccessible areas for the rapid & secure distribution of medical supplies and the war-torn regions from medical facilities.

In recent years, the usage of medical drones has been seeking the attention of healthcare providers and governments to offer better healthcare services to remote locations. These drones help in on-time delivery of vaccines, medication, blood, and supplies to the origin and thereby reduce the outbreaks of life-threatening infectious diseases.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/8596 

How can this technology help in improving safety and care delivery?

• Bedside medication delivery
• Effective treatment from the distance
• Easy reach to an isolated place
• Pre-treatment facility till the time emergency service arrives at takeover

Most of the key players in the market are focusing on developing medical drones to deliver medical supplies to far distances. For instance, in 2016, a Nevada based start-up Flirtey delivered medical test materials and supplies to and from an offshore vessel. This was the first successful ship to shore delivery in the U.S.

Market Influencer

Increasing investments by key players in R&D is the key factor driving the growth of the Global Medical Drones’ Market.

Market Drivers

• Rising participation of Governments in various countries: Active involvement of local governments towards the deployment of drone service to remote and isolated areas is boosting the growth of the market. For instance, in 2018, the government of Ghana has signed an agreement with Zipline (US) for the deployment of drones throughout the country to provide medical supplies to untapped regions

• Increasing application of drone for the supply of medical products such as blood, pharmaceuticals/drugs, and vaccines are anticipated to propel the market growth during the forecast period

• Technological advancements to improving the accuracy of medical drones during emergency cases backed by R&D activities by key players

• Rising public acceptance of medical drone is also driving the growth of the medical drone’s market

Market Restraints

• Medical drones. Medical drones are not allowed to fly without the permission of the government. Thus, product approval laws are expected to restrict the growth of the medical drone’s market during the forecast period.

Segmentation

By Application

• Blood Transfer: Rising incidence of severe bleeding deaths is boosting the demand for medical drones. The blood transfer segment is anticipated to show a growth rate of ~24% during the analysis period. According to the MRFR analysis, each year, around 60,000 Americans die from blood loss or hemorrhaging. Moreover, around 2 million people die across the globe.

• Pharmaceutical/Drugs Transfer: The increasing focus of key medical drones vendors towards the development of drones for medication delivery is boosting the growth of this segment.

• Vaccines Transfer: This segment is mainly on the drones that are associated with the delivery of the vaccine.

By End-User

• Emergency Medical Services: This segment held the largest market share in 2018, owing to continues advancements in technology. For instance, in 2019, an automated drone’s delivery company Zipline (US), has planned for the expansion of a medical drone network into Ghana for emergency services.

• Blood Banks: Owing to poor road conditions, transporting blood in underdeveloped countries is a huge task. Medical drones carry blood, plasma, and platelets from blood banks to remote hospitals and clinics.

By Region

• Americas: The Americas held the largest regional market in 2018, owing to rising technology advancement. Moreover, the governments in this region are also promoting the acceptance of medical drones, as a result, players are aggressively working to develop advanced drones. In October 2019, United Parcel Services (US) received an authority from the Federal Aviation Administration to deliver medical packages at hospitals across the country.

• Europe: The European market is expected to be the second-largest market in 2025. The market growth in this region can be attributed to government funding and support to the healthcare sector, coupled with increasing research and development.

• Asia-Pacific: Asia-Pacific is the fastest-growing region for the medical drones market owing to the improving healthcare infrastructure, rising investments in healthcare, and expansions by market players in the region. Also, countries such as India and China are expected to be the fastest-growing in the region due to the focus of governments towards the adoption of new technologies and faster adoption of best treatment options from developed countries.

• Middle East & Africa: It is projected to account for the least share of the global market due to an underdeveloped healthcare sector.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/medical-drones-market-8596 

Thalassemia Treatment Market Growth Analysis, Industry Trends, And Forecast By 2025

 Market Forecast

Thalassemia Treatment Market Size is expected to cross USD 3763 Million by 2025 at a CAGR of 10.4%.

Thalassemia, specifically the Beta- thalassemia disorder, is majorly caused by the mutation in the Hemoglobin Subunit Beta (HBB) gene. For instance, at least 5.2% of the world population and over 7% of pregnant women have a genetic mutation.

Market Synopsis

Thalassemia Treatment Market analysis asserts that, Thalassemia is an inherited blood disorder wherein the body makes an inadequate amount of hemoglobin. Hemoglobin disorders were initially prevalent in 60% of 229 countries, that potentially affected 75% of births, but are now sufficiently common in 71% of countries amongst 89% of births.

Market Influencers

Major companies are concentrating on mergers and acquisitions, new product developments, approvals, and regional expansions. For instance, in September 2019, Bluebird Bio, Inc. (US) has approved the first gene therapy for Beta-thalassemia. This gene therapy eliminates the need for blood transfusions in patients with β-thalassemia. Thus, major manufacturers are focusing on approvals in thalassemia treatment, which ultimately drives the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8595

Market Drivers

• The rising incidence of thalassemia is expected to drive the growth of the market. Patients with insufficient hemoglobin suffer from thalassemia. For instance, thalassemia affects approximately 4.4 of every 10,000 live births throughout the world.

• Increasing pipeline drugs in thalassemia is expected to drive the growth of the market. There are approximately 15 pipeline products under clinical trials for the treatment of thalassemia. For instance, in December 2016, Kiadis Pharma announced initiation of Phase I/II clinical trial with ATIR201 for thalassemia.

• A rise in awareness regarding available treatment options for the treatment of thalassemia is expected to drive the growth of the market.

• The rise in demand for improved curative gene therapy is expected to drive the growth of the market.

Market Restraints

• Stringent regulatory policies
• High treatment costs

Segmentation

By Type

• Alpha-thalassemia: Fastest growing segment. It is one of the most common autosomal recessive disorders. There is an increased incidence of the alpha-globin disorders in the US and other Western nations which eventually drives the growth of the thalassemia treatment market. However, about 5% of the world’s population is affected by alpha-thalassemia.

• Beta Thalassemia: It is caused by reduced or no production of beta-globin subunits. About 1.5% of the global population is affected by Beta-thalassemia.

By Treatment

• Blood Transfusions: The largest growing segment owing to the low risks involved due to careful blood screening. This treatment gives strong red blood cells along with normal hemoglobin. About 56,000 population have major thalassemia, wherein, at least 30,000 need regular blood transfusions. Thus, rising demand for blood transfusions is expected to drive the growth of the market.

• Iron Chelation Therapy: This includes removing excess iron from the bloodstream. Iron chelator drugs such as desferrioxamine, deferiprone, and deferasirox are majorly used in this treatment.

• Folic Acid Supplements: Folic acid is vitamin B that helps build strong red blood cells. These supplements are majorly consumed during and after pregnancy. However, 4% had started consuming after becoming pregnant. Thus, the increased use of folic acid is expected to drive the growth of this segment.

• Gene therapy: Scientists are investigating genetic techniques to treat thalassemia. Gene therapy named Zynteglo was first launched by Bluebird Bio, Inc. (US) in September 2019.

• Bone Marrow transplants: These transplants are not done very often as significant risks are involved but can be tried if no bone marrow matched donor is available. However, the patient will not need further blood transfusions if this transplantation is done. As a result, it would drive the market growth in this segment.

By End-User

• Hospitals & Clinics: Holds the largest market share owing to the increase in the number of hospital admissions for the treatment of thalassemia. Moreover, increasing occurrence of thalassemia is also expected to drive this segment.

• Diagnostic laboratories: This segment holds significant market share owing to the increasing awareness regarding thalassemia treatment.

• Others: This segment includes research laboratories, educational institutes, among others.

By Region

• Americas: The largest growing regional market owing to rising awareness about thalassemia and increasing government efforts to support gene therapy. However, Beta-thalassemia disorder is relatively rare in the US.

• Europe: The introduction of gene therapy for the treatment of thalassemia is expected to boost the growth of market. For instance, in September 2019, Bluebird Bio, Inc. (US) has obtained approval for gene therapy that would remove the need for blood transfusions for people with blood disorder beta-thalassemia.

• Asia-Pacific: The fastest-growing regional market in thalassemia treatment. Increasing investment in healthcare infrastructure is expected to drive the growth of the market in this region.

• Middle East & Africa: Increasing adoption rate of blood transfusion treatment in countries such as Turkey and GCC would drive the demand for thalassemia treatment in this region.

Key Players

• Novartis AG (Switzerland)
• Bluebird Bio, Inc. (US)
• Kiadis Pharma (Netherlands)
• CELGENE CORPORATION (US)
• Sangamo Therapeutics (US)
• Acceleron Pharma, Inc. (US)
• Gamida Cell (Israel)

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/thalassemia-treatment-market-8595